Clinical Trials Logo

IgG4-RD clinical trials

View clinical trials related to IgG4-RD.

Filter by:
  • None
  • Page 1

NCT ID: NCT04918147 Terminated - Clinical trials for IgG4 Related Disease

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Start date: October 13, 2021
Phase: Phase 2
Study type: Interventional

This is a two-part multi-center clinical trial in participants with active IgG4-RD. Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD. Part 2 (Cohort 2) is a randomized, placebo-controlled, double-blinded (masked) trial phase to compare the effects of elotuzumab and prednisone to elotuzumab placebo and prednisone in participants with IgG4 RD. Approximately 75 participants with active IgG4-RD will be enrolled in the overall program, 12 in Part 1 and 63 in Part 2. Randomization in Part 2: 2 to 1, with approximately forty-two participants randomized to elotuzumab plus prednisone taper, and twenty-one participants randomized to placebo for elotuzumab plus prednisone taper. The total duration of participation for each participant in this trial will be 48 weeks (11 months).

NCT ID: NCT02725476 Completed - IgG4-RD Clinical Trials

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity